Amparo Garcia-Tejedor MD, PhD; 2026 EBCC: Axillary Radiotherapy Seems As Effective as Axillary Lymphadenectomy in Sentinel Node Positive Early Breast Cancer, with Less Risk of Lymphedema

About this episode

The episode discusses the effectiveness of axillary radiotherapy compared to axillary lymphadenectomy in early breast cancer treatment, featuring insights from Dr. Amparo Garcia-Tejedor.

Axillary Radiotherapy Seems As Effective as Axillary Lymphadenectomy in Sentinel Node Positive Early Breast Cancer, with Less Risk of Lymphedema An interview with: Amparo Garcia-Tejedor MD, PhD, Professor of Gynecology, University of Barcelona, Bellvitge University Hospital, Instituto de Investigación Biomédica de Bellvitge, Barcelona, Spain. BARCELONA, Spain—Early results from the ADARNAT study have found that using axillary radiotherapy after neoadjuvant therapy and surgery for women with sentinel node positive early breast cancer was as effective removing lymph nodes while bringing a lower risk of lymphedema. These preliminary finding were reported at the 2026 European Breast Cancer Conference by Amparo Garcia-Tejedor MD, PhD, Professor of Gynecology at the University of Barcelona’s Bellvitge Hospital, in Barcelona, Spain. Afterwards she gave more details to our reporter, Peter Goodwin: AUDIO JOURNAL OF ONCOLOGY: Amparo Garcia-Tejedor MD, PhD IN: [GOODWIN]”Peter Goodwin here in….. OUT: …..of Oncology, I’m Peter Goodwin 6:36secs EBCC Abstract 7: Axillary radiotherapy as an alternative to axillary dissection for node-positive breast cancer after neoadjuvant therapy: two-year…

People in this episode

Host: Peter Goodwin

Guest: Amparo Garcia-Tejedor MD, PhD

Topics covered

• axillary radiotherapy
• breast cancer
• lymphedema
• neoadjuvant therapy
• surgery
• ADARNAT study

Keywords

• axillary radiotherapy
• axillary lymphadenectomy
• sentinel node positive
• early breast cancer
• lymphedema risk
• ADARNAT study
• European Breast Cancer Conference

Mentioned in this episode

Organizations: University of Barcelona, Bellvitge University Hospital, Instituto de Investigación Biomédica de Bellvitge

Places: Barcelona, Spain

More episodes of Audio Journal of Oncology Podcast

• Jonathan Wesley Riess MD; 2026 AACR: Investigational KRAS(ON) Inhibitor Zoldonrasib Showed Effective and Durable Responses in Patients With Advanced G12D-mutated Lung Cancer · May 6, 2026 · 8 min
• Marija Balic MD PhD, AACR 2026: Whole Exome Sequencing of ctDNA Informs Post-Neoadjuvant Therapy Options for Patients with Triple Negative Early Breast Cancer · April 30, 2026 · 11 min
• Tao Zhu MD; AACR 2026: Anti-Claudin 6 Antibody Drug Conjugate Benefits Patients with Advanced Platinum-Resistant Ovarian Cancer with Low Toxicity · April 28, 2026 · 5 min
• Moran Amit MD PhD; AACR 2026: Oral Intralesional PD 1 Blockade Promises Less Risk of Progression to Oral Cancer than Surgery, with Preserved Quality of Life · April 27, 2026 · 10 min
• Byoung Chul Cho MD PhD; AACR 2026: New Generation KRAS G12C Inhibitor Brings Promising Responses Even in Patients with Advanced Lung Cancers Refractory to Previous KRAS-targeted Therapy · April 24, 2026 · 8 min
• Elena Garralda MD PhD, AACR 2026: Molecular Glue Degrader Improves Outcomes in Heavily Pre-treated Patients with Advanced Solid Tumors · April 23, 2026 · 9 min